Hims to offer brand-name GLP-1s despite snub from Eli Lilly: Hims appears to have burned bridges with the two biggest GLP-1 drugmakers and consequently could lose customers to rivals selling weight loss drugs at a discount.
Pharma companies sidestepped the Trump administration's broad tariff orders: It’s a pharma win for tariffs, but the president’s comments on foreign tax breaks and manufacturing reshoring demands still signal potential for challenges ahead.
FTC pauses lawsuit against Big 3 PBMs: But we don’t envision the case falling apart. There’s too much bipartisan support around lessening the influence PBMs have over drug pricing and pharmacy reimbursement.
Once valued at $100 billion in 2015, Walgreens Boots Alliance has seen its market value plummet to approximately $10 billion today, with shares down 45% in the last 12 months—making it the worst-performing stock in the S&P 500 in 2024.
AI medical scribes reduce doctor burnout, but cost savings are unclear: A new report highlights tactical benefits of the tech for health systems, but tech companies need to demonstrate how their tools deliver long-term financial benefits.
Oura debuts AI Advisor, Apple plans AI doctor in health app revamp: AI health agents add personalized advice and recommendations, but they should be viewed as helpful advice versus medical assessments.
Top vaccine official at FDA forced out by RFK Jr., Makary: It’s becoming clearer that Kennedy will surround himself with people who share his viewpoints on vaccines.
Novo Nordisk inks licensing agreement for oral weight loss drug candidate: Novo wants to find out if patients could benefit from a weight loss drug pill after they use one of its blockbuster GLP-1s.
Eli Lilly adds Alzheimer’s treatments, resources to D2C platform: Lilly is progressing its D2C online offerings even as lawmakers ramp up scrutiny of drugmaker-telehealth partnerships.
Consumers reject AI-written doctor’s notes: Patients' demand for transparent messaging from physicians is a reminder for pharma and healthcare companies to make sure their marketing messages are transparent too.
Makary named FDA commissioner, federal health agency layoffs could soon follow: Pharma companies could face slower approvals and more scrutiny of their products, treatments, and prices.
Amazon tests AI chatbot for consumer health questions: Amazon’s experimental Health AI chatbot could drive engagement with its One Medical and pharma services..
26% of US adults take 4+ prescription drugs daily: This cohort is the most likely to struggle with affording their meds. Pharma marketers need to raise awareness of cost-saving offerings to boost medication adherence among patients.
23andMe files for bankruptcy: A sale could give the acquiring company access to 15 million people’s genetic data. 23andMe’s downfall is a reminder of the risks when tech companies collect sensitive health data and struggle to sufficiently protect it.
Consumers blame Insurers, pharma for the state of US healthcare: Both industries continue to face serious trust issues with consumers that marketing alone won’t fix.
Self-pay patients can now get discounted Wegovy at retail pharmacies: It’s a smart play on the part of Novo Nordisk to make its GLP-1 available at pharmacies where most consumers still get their prescriptions. Will rival Eli Lilly follow suit?
Peloton owns half of all at-home fitness market sales, according to a February Earnest Analytics survey.
Pharmacy deserts increase across the US, mostly in rural areas: More pharmacy closures are expected, which means medication access for many patients will worsen before it improves.
Weight loss drug ads are prevalent on digital media: But these ads are often misleading, and younger consumers are particularly at risk of falling for deceptive weight loss drug offerings.
Nurses are still in short supply: There are efforts to improve nurse satisfaction. But more nurses are quitting than being hired, and patients’ trust in quality of care is at risk.